Want to see TSE:SVA full AI Analyst Report?
SVA Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.21
Previous CloseN/A
Volume46.74K
Average Volume (3M)125.66K
Market Cap
C$43.43M
Enterprise ValueC$60.51M
Total Cash (Recent Filing)C$1.05M
Total Debt (Recent Filing)C$2.45M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Sep 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding377,642,520
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Bulls Say, Bears Say
Bulls Say
Platform-led FranchiseA proprietary implantable Cell Pouch platform creates a durable competitive advantage: it is designed to vascularize and sustain therapeutic cells, enabling repeated applications across diabetes and other cell therapies. A successful platform supports scalable indication expansion and long-term commercial optionality.
Improving Loss TrendA sustained narrowing of operating losses and year-over-year improvement shows management improving cost discipline and R&D efficiency. For a pre-revenue biotech, this reduces near-term financing pressure, extends runway, and increases the probability of reaching key clinical inflection points without immediate dilution.
Lean Operating FootprintA very small employee base indicates a low fixed-cost structure and operational flexibility. For a clinical-stage biotech, lean operations can conserve cash, allow targeted outsourcing of trials and manufacturing, and prolong runway while advancing critical clinical milestones.
Bears Say
Pre-revenue ProfileNo revenue and ongoing operating losses mean the company must rely on external funding until commercialization. This structural profile elevates execution risk, makes sustained investment necessary for late-stage development, and leaves outcomes highly binary dependent on clinical success.
Negative Shareholders' EquityNegative equity and shrinking assets materially weaken financial flexibility. This structural balance-sheet deterioration constrains borrowing capacity, increases creditor scrutiny, and heightens insolvency or restructuring risk if operational performance or financing access deteriorates.
Persistent Cash BurnConsistent negative operating and free cash flow requires repeated capital raises or partnerships. Dependency on external financing is a durable vulnerability that can dilute shareholders, delay programs if funding is scarce, and makes timelines contingent on capital markets and partner interest.
Sernova News
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.10 and its highest was C$0.20 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$43.43M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Sep 10, 2026 which is in 41 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Jun 11, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Overvalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is 0.
How many shares outstanding does Sernova have?
Sernova has 377,642,520 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―